Article
An engineered antibody fragment targeting mutant β-catenin via major histocompatibility complex I neoantigen presentation.
The Journal of biological chemistry - 13 Dec 2019
Miller Michelle S, Douglass Jacqueline, Hwang Michael S, Skora Andrew D, Murphy Michael, Papadopoulos Nickolas, Kinzler Kenneth W, Vogelstein Bert, Zhou Shibin, Gabelli Sandra B
Abstract excerpt
Mutations in CTNNB1, the gene encoding β-catenin, are common in colon and liver cancers, the most frequent mutation affecting Ser-45 in β-catenin. Peptides derived from WT β-catenin have previously been shown to be presented on the cell surface as part of major histocompatibility complex (MHC) class I, suggesting an opportunity for targeting this common driver gene mutation with antibody-based therapies. Here,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.